questionsmedicales.fr
Cellules
Cellules épithéliales
Hépatocytes
Cellules HepG2
Cellules HepG2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules HepG2 : Questions médicales les plus fréquentes",
"headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-11",
"dateModified": "2025-05-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules HepG2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hépatocytes",
"url": "https://questionsmedicales.fr/mesh/D022781",
"about": {
"@type": "MedicalCondition",
"name": "Hépatocytes",
"code": {
"@type": "MedicalCode",
"code": "D022781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436.348"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules HepG2",
"alternateName": "Hep G2 Cells",
"code": {
"@type": "MedicalCode",
"code": "D056945",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wilson de Melo Cruvinel",
"url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com."
}
},
{
"@type": "Person",
"name": "Paulo Luiz Carvalho Francescantonio",
"url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil."
}
},
{
"@type": "Person",
"name": "Alessandra Dellavance",
"url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance",
"affiliation": {
"@type": "Organization",
"name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Luis Eduardo Coelho Andrade",
"url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br."
}
},
{
"@type": "Person",
"name": "Antônio Carlos Ximenes",
"url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes",
"affiliation": {
"@type": "Organization",
"name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Translating musculoskeletal bioengineering into tissue regeneration therapies.",
"datePublished": "2022-10-12",
"url": "https://questionsmedicales.fr/article/36223445",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/scitranslmed.abn9074"
}
},
{
"@type": "ScholarlyArticle",
"name": "Epitranscriptional Regulation: From the Perspectives of Cardiovascular Bioengineering.",
"datePublished": "2023-03-08",
"url": "https://questionsmedicales.fr/article/36913673",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1146/annurev-bioeng-081922-021233"
}
},
{
"@type": "ScholarlyArticle",
"name": "On-Chip Octanol-Assisted Liposome Assembly for Bioengineering.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/37010275",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3791/65032"
}
},
{
"@type": "ScholarlyArticle",
"name": "Salivary gland bioengineering - yesterday, today, tomorrow!",
"datePublished": "2023-01-03",
"url": "https://questionsmedicales.fr/article/36637107",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14670/HH-18-580"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases.",
"datePublished": "2022-07-01",
"url": "https://questionsmedicales.fr/article/35778828",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/adbi.202200087"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hépatocytes",
"item": "https://questionsmedicales.fr/mesh/D022781"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cellules HepG2",
"item": "https://questionsmedicales.fr/mesh/D056945"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules HepG2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules HepG2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules HepG2",
"description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Bioengineering&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules HepG2",
"description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Bioengineering&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules HepG2",
"description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Bioengineering&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules HepG2",
"description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Bioengineering&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules HepG2",
"description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Bioengineering&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules HepG2",
"description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Bioengineering&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules HepG2 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine."
}
},
{
"@type": "Question",
"name": "Quelles techniques sont utilisées pour étudier les HepG2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 présentent-elles des symptômes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux cellules HepG2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 contribuent-elles à la recherche préventive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser HepG2 pour tester des médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 aident-elles à développer des traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être étudiées avec HepG2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées."
}
},
{
"@type": "Question",
"name": "Les HepG2 aident-elles à comprendre les complications du foie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec HepG2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Comment HepG2 aide à identifier des facteurs de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques."
}
}
]
}
]
}
Musculoskeletal injuries and disorders are the leading cause of physical disability worldwide and a considerable socioeconomic burden. The lack of effective therapies has driven the development of nov...
The central dogma of gene expression involves DNA transcription to RNA and RNA translation into protein. As key intermediaries and modifiers, RNAs undergo various forms of modifications such as methyl...
Microfluidics is a widely used tool to generate droplets and vesicles of various kinds in a controlled and high-throughput manner. Liposomes are simplistic cellular mimics composed of an aqueous inter...
Salivary glands are specialized structures developed as an extensively compact, arborized design through classical embryogenesis, accompanied by a cascade of events channelized by numerous growth fact...
Cardiovascular diseases (CVD) remain one of the leading causes of mortality worldwide. Despite recent advances in diagnosis and interventions, there is still a crucial need for new multifaceted therap...
The thymus coordinates the development and selection of T cells. It is structured into two main compartments: the cortex and the medulla. The replication of such complex 3D environment has been challe...
Tailoring the structure of cellulose, hemicellulose or pectin in plant cell walls can modulate growth, disease resistance, biomass yield and other important agronomic traits. Recent advances in the bi...
Over the past decade, stem cell- and tumor-derived organoids are the most promising models in developmental biology and disease modeling, respectively. The matrix is one of three main elements in the ...
RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfe...
Soybean is a major oil crop and is also a dominant source of nutritional protein. The 20% seed oil content (SOC) of soybean is much lower than that in most oil crops and the fatty acid composition of ...